Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Aug 1;80(8):813-823.
doi: 10.1001/jamaneurol.2023.1835.

Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis

Emile d'Angremont  1 , Marieke J H Begemann  1 , Teus van Laar  2 , Iris E C Sommer  3
Affiliations
Meta-Analysis

Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis

Emile d'Angremont et al. JAMA Neurol. .

Abstract

Importance: Psychotic symptoms greatly increase the burden of disease for people with neurodegenerative disorders and their caregivers. Cholinesterase inhibitors (ChEIs) may be effective treatment for psychotic symptoms in these disorders. Previous trials only evaluated neuropsychiatric symptoms as a secondary and an overall outcome, potentially blurring the outcomes noted with ChEI use specifically for psychotic symptoms.

Objective: To quantitatively assess the use of ChEIs for treatment of individual neuropsychiatric symptoms, specifically hallucinations and delusions, in patients with Alzheimer disease (AD), Parkinson disease (PD), and dementia with Lewy bodies (DLB).

Data sources: A systematic search was performed in PubMed (MEDLINE), Embase, and PsychInfo, without year restrictions. Additional eligible studies were retrieved from reference lists. The final search cutoff date was April 21, 2022.

Study selection: Studies were selected if they presented the results of placebo-controlled randomized clinical trials, including at least 1 donepezil, rivastigmine, or galantamine treatment arm in patients with AD, PD, or DLB; if they applied at least 1 neuropsychiatric measure including hallucinations and/or delusions; and if a full-text version of the study was available in the English language. Study selection was performed and checked by multiple reviewers.

Data extraction and synthesis: Original research data were requested on eligible studies. A 2-stage meta-analysis was then performed, using random-effects models. Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were followed for extracting data and assessing the data quality and validity. Data extraction was checked by a second reviewer.

Main outcomes and measures: Primary outcomes were hallucinations and delusions; secondary outcomes included all other individual neuropsychiatric subdomains as well as the total neuropsychiatric score.

Results: In total, 34 eligible randomized clinical trials were selected. Individual participant data on 6649 individuals (3830 [62.6%] women; mean [SD] age, 75.0 [8.2] years) were obtained from 17 trials (AD: n = 12; PD: n = 5; individual participant data were not available for DLB). An association with ChEI treatment was shown in the AD subgroup for delusions (-0.08; 95% CI, -0.14 to -0.03; P = .006) and hallucinations (-0.09; 95% CI, -0.14 to -0.04; P = .003) and in the PD subgroup for delusions (-0.14; 95% CI, -0.26 to -0.01; P = .04) and hallucinations (-0.08, 95% CI -0.13 to -0.03; P = .01).

Conclusions and relevance: The results of this individual participant data meta-analysis suggest that ChEI treatment improves psychotic symptoms in patients with AD and PD with small effect sizes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Mr d’Angremont reported receiving grants from ZonMW during the conduct of the study. Dr van Laar reported receiving personal fees from AbbVie, Clexio, and Supernus Pharmaceuticals for advisory board participation and lectures, from Britannia for lectures, and grants from Stada Arzneimittel outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Study Flow Diagram of Literature Search and Included Studies and Data
IPD indicates individual participant data; RCT, randomized clinical trial.
Figure 2.
Figure 2.. Effect Sizes of Cholinesterase Inhibitor Treatment in Delusions (A) and Hallucinations (B)
Results are separated for Alzheimer disease (AD) and Parkinson disease (PD). Square size denotes weighting. The diamonds reflect the overall effect size. SMD indicates standardized mean difference.
Figure 3.
Figure 3.. Treatment Effect Sizes of Cholinesterase Inhibitors in Individual Neuropsychiatric Items
Results are separated for Alzheimer disease (AD) and Parkinson disease (PD). Error bars indicate the 95% CIs.
Figure 4.
Figure 4.. Effect Sizes of Cholinesterase Inhibitor Treatment in Total Neuropsychiatric Outcome
Results are separated for Alzheimer disease (AD) and Parkinson disease (PD). Square size denotes weighting. The diamonds reflect the overall effect size. SMD indicates standardized mean difference.
See this image and copyright information in PMC

Comment in

  • Cholinesterasehemmer gegen Psychosen.
    Duning T. Duning T. MMW Fortschr Med. 2024 Apr;166(7):27-28. doi: 10.1007/s15006-024-3872-9. MMW Fortschr Med. 2024. PMID: 38637378 Review. German. No abstract available.

References

    1. Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer’s disease: review of the brain decade. Psychosomatics. 2003;44(5):388-401. doi:10.1176/appi.psy.44.5.388 - DOI - PubMed
    1. Linszen MMJ, Lemstra AW, Dauwan M, Brouwer RM, Scheltens P, Sommer IEC. Understanding hallucinations in probable Alzheimer’s disease: very low prevalence rates in a tertiary memory clinic. Alzheimers Dement (Amst). 2018;10:358-362. doi:10.1016/j.dadm.2018.03.005 - DOI - PMC - PubMed
    1. McKeith IG, Boeve BF, Dickson DW, et al. . Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058 - DOI - PMC - PubMed
    1. Fénelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763-766. doi:10.1002/mds.22839 - DOI - PMC - PubMed
    1. Fénelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010;289(1-2):12-17. doi:10.1016/j.jns.2009.08.014 - DOI - PubMed

Publication types